Effect observation of 47 patients with breast milk jaundice treated by combined Bifid Triple Viable Capsule(En.sol.) and Smecta

Li Jie,Tang Xiaoyan,Lan Lin
DOI: https://doi.org/10.3969/j.issn.1672-1721.2007.23.010
2007-01-01
Abstract:Objective To investigate the effect of combined Bifid Triple Viable Capsule(En.sol.) and Smecta in the treatment of breast milk jaundice.Methods 93 neonates with breast milk jaundice were divided into two groups.The treatment group had 47 cases and the control group had 46 cases.In the control group,Phenobarbital was taken by the neonate.In addition to what were administered in the control group,the Bifid Triple Viable Capsule(En.sol.) and Smecta were used in the treatment group.Results The excellence rate in the treatment group was 48.9%,the total effective ratio was 91.4%,which was significantly higher than in the control group(P<0.01).Conclusion The treatment of Bifid Triple Viable Capsule(En.sol.)and Smecta on breast milk jaundice was effective and safe and it would lessen hemobilirubin rapidly,shorted treat time.
What problem does this paper attempt to address?